{"type":"trials","record":{"id":42176,"source_id":"clinicaltrials-gov","external_id":"NCT05480293","title":"This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD","brief_summary":"The purpose of this study is to compare the efficacy and safety of SCT510A versus Lucentis in the treatment of wet age-related macular degeneration.","overall_status":"Unknown","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Sinocelltech Ltd.","enrollment":446,"countries":["China"],"start_date":"2023-02-14","completion_date":"2025-08-31","last_update_date":"2023-02-16","source_url":"https://clinicaltrials.gov/study/NCT05480293","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"45 Years","comparator":"Ranibizumab","organization":"Sinocelltech Ltd.","interventions":["Ranibizumab","SCT510A"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change from baseline in BCVA at at Week 48 — up to at Week 48","Proportion of patients gaining at least 5，10，15 letters in the BCVA at Week 12, 24 and 48 — up to Week 12, 24 and 48","Mean change from baseline in BCVA at at Week 12 and 24 — up to Week 12 and 24","Mean change from baseline in CRT on OCT at Week 12, 24 and 48 (as measured by the Reading Center) — up to Week 12,24 an…","Mean change from baseline in size of CNV and total area of fluorescein leakage from CNV on FA at Week 12 and 48 (as mea…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","Ranibizumab","SCT510A"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05480293","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-02-14 to 2025-08-31","comparator":"Ranibizumab","confidence":"structured-source","population":"ALL · 45 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.930Z","intervention":["Ranibizumab","SCT510A"],"participants":446,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change from baseline in BCVA at at Week 48 — up to at Week 48","Proportion of patients gaining at least 5，10，15 letters in the BCVA at Week 12, 24 and 48 — up to Week 12, 24 and 48","Mean change from baseline in BCVA at at Week 12 and 24 — up to Week 12 and 24","Mean change from baseline in CRT on OCT at Week 12, 24 and 48 (as measured by the Reading Center) — up to Week 12,24 an…","Mean change from baseline in size of CNV and total area of fluorescein leakage from CNV on FA at Week 12 and 48 (as mea…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42176","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}